Candel Therapeutics
CADL
9.57
-0.26
-2.60%
Candel Therapeutics
US · CADL
#3461 by market cap
Listed 2021
9.57
-0.26
-2.60%
Live - 5344 symbols - heartbeat 485s ago
· 2026-10-08 10:00
Pre-market
9.82
-0.02%
After-hours
9.83
+0.10%
- Market cap
- 731.90M
- P/E (TTM)i
- -6.51
- P/Bi
- 5.80
- EPSi
- -0.72
- Div yieldi
- 0.00%
- 52W posi
- 54%
Reader sentiment
Are you bullish or bearish on CADL?
Anonymous reader poll. Unscientific, not investment advice.
About Candel Therapeutics
Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
- Founded
- 2002
- CEO
- Dr. Paul Peter Tak, M.D.,PhD
- Employees
- 55
- Headquarters
- Needham, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- candeltx.com
Company profile
- Exchange
- US
- Symbol
- CADL
- Market-cap rank
- #3461
- Listing date
- 2021-07-27
- Market cap
- 731.90M
- Float cap
- 576.00M
- Shares out
- 76.52M
- Float shares
- 60.22M
Sectors & themes
Biotechnology
Quote time 2026-10-08 10:00:27 · For reference only, not investment advice and not tailored to your situation.